FIRST TIME GENERIC APPROVAL

Brand Name	Rosuvastatin and ezetimibe
Generic Name	rosuvastatin and ezetimibe
Drug Manufacturer	Althera Pharms

New Drug Approval

TYPE OF CLINICAL UPDATE

First Time Generic

FDA APPROVAL DATE

March 23, 2021

LAUNCH DATE

August 15, 2021

REVIEW DESIGNATION

Type 4 - New Combination

TYPE OF REVIEW

New Drug Application (NDA): 213072

DISPENSING RESTRICTIONS

N/A

Overview

INDICATION FOR USE

Rosuvastatin and ezetimibe tablets is a combination of HMG CoA-reductase inhibitor (statin), and a dietary cholesterol absorption inhibitor, indicated in adults:

- As an adjunct to diet in patients with primary non-familial hyperlipidemia to reduce low-density lipoprotein cholesterol (LDL- C).
- Alone or as an adjunct to other LDL-C lowering therapies in patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C.

MECHANISMS OF ACTION

Rosuvastatin
Rosuvastatin is an inhibitor of HMG CoA-reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a precursor of cholesterol. In in vivo and in vitro studies, rosuvastatin produces its lipid-modifying effects in two ways. First, it increases the number of hepatic LDL receptors on the cell-surface to enhance uptake and catabolism of LDL. Second, rosuvastatin inhibits hepatic synthesis of VLDL, which reduces the total number of VLDL and LDL particles.

Ezetimibe
The molecular target of ezetimibe is the sterol transporter, Niemann-Pick C1-Like 1 (NPC1L1), which is involved in the intestinal uptake of cholesterol and phytosterols. Ezetimibe localizes at the brush border of the small intestine

and inhibits the absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the liver. This causes a reduction of hepatic cholesterol stores and an increase in clearance of cholesterol from the blood.

DOSE FORM AND STRENGTH

Tablets (rosuvastatin/ezetimibe): 5 mg/10 mg, 10 mg/10 mg, 20 mg/10 mg, 40 mg/10 mg.

DOSE & ADMINISTRATION

- Swallow tablets whole; do not crush, dissolve, or chew.
- Dosage range is 5 mg/10 mg to 40 mg/10 mg once daily.
- Recommended dosage depends on the indication for usage, LDL- C, and individual risk for cardiovascular events.
- Assess LDL-C as early as 2 weeks after initiating rosuvastatin and ezetimibe tablets and adjust dosage as necessary.
- Asian patients: Initiate at 5 mg/10 mg once daily.
- Patients with severe renal impairment (not on hemodialysis): initiate at 5 mg/10 mg once daily; do not exceed 10 mg/10 mg once daily.
- Administer rosuvastatin and ezetimibe tablets at least 2 hours before or 4 hours after administration of a bile acid sequestrant.
- Administer rosuvastatin and ezetimibe tablets at least 2 hours before administration of an aluminum and magnesium hydroxide combination antacid.